Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study

Background Upadacitinib (UPA), an oral Janus kinase inhibitor, has shown efficacy with an acceptable safety profile in rheumatoid arthritis (RA) clinical trials. Objective To assess the real-world effectiveness and safety of UPA in adults with moderate-to-severe RA in the UPHOLD observational study....

Full description

Saved in:

Bibliographic Details
Published in:	Arthritis research & therapy 2025-04, Vol.27 (1), p.84-14, Article 84
Main Authors:	Östör, Andrew, Feist, Eugen, Sidiropoulos, Prodromos, Avouac, Jérôme, Rebella, Martin, Namas, Rajaie, McDearmon-Blondell, Erin, Gao, Tianming, Lagunes-Galindo, Ivan, Strengholt, Sander, Zisman, Devy, Attar, Suzan
Format:	Article
Language:	English
Subjects:	Adalimumab Adult Aged Analysis Antiarthritic agents Antirheumatic Agents - adverse effects Antirheumatic Agents - therapeutic use Arthritis Arthritis, Rheumatoid - drug therapy C-reactive protein Care and treatment Clinical medicine Clinical trials Consent Disease control Drug dosages Drug therapy Effectiveness Female Heterocyclic Compounds, 3-Ring - adverse effects Heterocyclic Compounds, 3-Ring - therapeutic use Humans Janus Kinase Inhibitors - therapeutic use Kinases Laboratories Male Medicine Medicine & Public Health Middle Aged Observational studies Orthopedics Patient outcomes Patients Performance evaluation Pharmacology, Experimental Physiological aspects Real-world Remission (Medicine) Remission Induction Rheumatoid arthritis Rheumatoid factor Rheumatology Safety Severity of Illness Index Treatment Outcome Tumor necrosis factor-TNF Upadacitinib
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!